Treatment outcomes in cytomegalovirus anterior uveitis.
Humans
Male
Female
Middle Aged
Cytomegalovirus Infections
/ drug therapy
Uveitis, Anterior
/ drug therapy
Antiviral Agents
/ therapeutic use
Retrospective Studies
Treatment Outcome
Ganciclovir
/ therapeutic use
Aged
Cytomegalovirus
Adult
Valganciclovir
/ therapeutic use
Recurrence
Ophthalmic Solutions
CMV anterior uveitis
CMV treatment
Systemic ganciclovir
Topical ganciclovir
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 07 2024
02 07 2024
Historique:
received:
10
03
2024
accepted:
28
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
This retrospective cohort study investigated patients with cytomegalovirus anterior uveitis (CMV AU) and compared treatment outcomes between regional and systemic antiviral therapies. Treatment modalities included topical (2% ganciclovir [GCV] eye drops or 0.2% GCV eye gel) and systemic (intravenous GCV or oral valganciclovir) groups. The comparison parameters included response rates, time to response, recurrence rates, time to recurrence, and complications. Forty-four patients (54.5% male) with a mean age of 56 ± 9.87 years were enrolled, with 31 eyes in the topical group and 13 eyes in the systemic group. The median response time was significantly slower in the topical group (63 days [IQR 28-112]) compared to the systemic group (28 days [IQR 24-59]) (p = 0.04). Treatment response rates were 87.1% (27/31) in the topical group and 100% (13/13) in the systemic group (p = 0.30), while recurrence rates were 37% (10/27) and 69.2% (9/13) (p = 0.056), with a median time to recurrence of 483 days [IQR 145-1388] and 392 days [IQR 203.5-1907.5] (p = 0.20), respectively. In conclusion, both topical and systemic GCV treatments demonstrated favorable outcomes for CMV AU. Systemic GCV showed rapid control of intraocular inflammation.
Identifiants
pubmed: 38956212
doi: 10.1038/s41598-024-66224-5
pii: 10.1038/s41598-024-66224-5
doi:
Substances chimiques
Antiviral Agents
0
Ganciclovir
P9G3CKZ4P5
Valganciclovir
GCU97FKN3R
Ophthalmic Solutions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15210Informations de copyright
© 2024. The Author(s).
Références
Chan, N. S., Chee, S. P., Caspers, L. & Bodaghi, B. Clinical features of CMV-associated anterior uveitis. Ocul. Immunol. Inflamm. 26(1), 107–115 (2018).
doi: 10.1080/09273948.2017.1394471
pubmed: 29172842
Zhang, J., Kamoi, K., Zong, Y., Yang, M. & Ohno-Matsui, K. Cytomegalovirus anterior uveitis: Clinical manifestations, diagnosis, treatment, and immunological mechanisms. Viruses 15(1), 185 (2023).
doi: 10.3390/v15010185
pubmed: 36680225
pmcid: 9867175
Koizumi, N. et al. Clinical features and management of cytomegalovirus corneal endotheliitis: Analysis of 106 cases from the Japan corneal endotheliitis study. Br. J. Ophthalmol. 99(1), 54–58 (2015).
doi: 10.1136/bjophthalmol-2013-304625
pubmed: 25075122
Maxwell Elia, M., John, J. H., Paul, A. & Gaudio, M.D. Cytomegalovirus anterior uveitis in immunocompetent patients. Ophthalmic pearls (2016)
Chee, S. P. & Jap, A. Cytomegalovirus anterior uveitis: Outcome of treatment. Br. J. Ophthalmol. 94(12), 1648–1652 (2010).
doi: 10.1136/bjo.2009.167767
pubmed: 20576767
Wong, J. X., Agrawal, R., Wong, E. P. & Teoh, S. C. Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis. J. Ophthalmic. Inflamm. Infect. 6(1), 10 (2016).
doi: 10.1186/s12348-016-0078-z
pubmed: 26976016
pmcid: 4791412
Keorochana, N. & Choontanom, R. Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis. BMJ Open Ophthalmol. 2(1), e000061 (2017).
doi: 10.1136/bmjophth-2016-000061
pubmed: 29354718
pmcid: 5721646
Zhai, R. Y., Xu, H., Kong, X. M. & Wang, Z. J. Effect of 2% ganciclovir eye drops on cytomegalovirus positive Posner–Schlossman syndrome. Zhonghua Yan Ke Za Zhi 54(11), 833–838 (2018).
pubmed: 30440154
Jabs, D. A., Nussenblatt, R. B. & Rosenbaum, J. T. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 140(3), 509–516 (2005).
doi: 10.1016/j.ajo.2005.03.057
pubmed: 16196117
Accorinti, M. et al. Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients. Graefes Arch. Clin. Exp. Ophthalmol. 252(11), 1817–1824 (2014).
doi: 10.1007/s00417-014-2782-4
pubmed: 25138606
Thng, Z. X. et al. The infectious uveitis treatment algorithm network (TITAN) report 2-global current practice patterns for the management of Cytomegalovirus anterior uveitis. Eye (Lond.) 38(1), 68–75 (2024).
doi: 10.1038/s41433-023-02631-8
pubmed: 37419958
Gourin, C., Alain, S. & Hantz, S. Anti-CMV therapy, what next? A systematic review. Front. Microbiol. 14, 1321116 (2023).
doi: 10.3389/fmicb.2023.1321116
pubmed: 38053548
pmcid: 10694278
Chen, P. J. et al. Long-term outcome of treatment with 2% topical ganciclovir solution in cytomegalovirus anterior uveitis and corneal endotheliitis. Infect. Drug Resist. 15, 3395–3403 (2022).
doi: 10.2147/IDR.S370905
pubmed: 35791348
pmcid: 9250767
Mori, K. et al. Clinical features of glaucoma associated with cytomegalovirus corneal endotheliitis. Clin. Ophthalmol. 16, 2705–2711 (2022).
doi: 10.2147/OPTH.S376039
pubmed: 36017508
pmcid: 9397528
Touhami, S. et al. Cytomegalovirus anterior uveitis: clinical characteristics and long-term outcomes in a French series. Am. J. Ophthalmol. 194, 134–142 (2018).
doi: 10.1016/j.ajo.2018.07.021
pubmed: 30055154